Related Experiment Video
Updated: Jan 15, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Factor X and combined factor VIIa/factor X augment coagulation potential in a plasma model of antithrombin-reduced
Shigeharu Oh1,2, Yuto Nakajima1,2, Eisuke Takami3
1Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
Background:
Plasma-derived (pd) factor (F)VIIa/FX products are available for the hemostatic management of people with hemophilia with inhibitors in Japan. We have previously reported that FX alone augments emicizumab-driven hemostasis. Fitusiran is an investigational small interfering RNA that reduces antithrombin (AT) to rebalance hemostasis in people with hemophilia. The effects of supplementation with pd-FVIIa/FX or FX alone on coagulation potential in AT-reduced hemophilia remain to be clarified.
Objectives:
To assess the coagulation potential of pd-FVIIa/FX or FX using an in vitro model of AT-reduced (fitusiran-treated) people with hemophilia.
Methods:
Pd-FVIIa/FX (0.75 and 1.5 μg/mL as FVIIa), recombinant FVIIa (1.1 and 2.2 μg/mL), activated prothrombin complex concentrate (0.65 and 1.3 IU/mL), or FX (260 and 520 nM) were added to FVIII- or FIX-depleted AT-deficient plasmas at AT levels of 10% and 30% (AT-reduced model). Additionally, FX (0-1040 nM) was incubated with FVIII- or FIX-depleted FX-deficient plasmas to assess FVIIa/tissue factor (TF)-mediated FX activation. Coagulation potential was assessed by measuring thrombin generation (TG) and FXa.
Results:
The addition of pd-FVIIa/FX, activated prothrombin complex concentrate, or FX to the AT-reduced plasma model of people with hemophilia improved TG potential within the normal range. The addition of recombinant FVIIa, however, had little effect on TG in this model. The addition of FX to FVIII- or FIX-depleted FX-deficient plasma increased TG potential and FVIIa/TF-triggered FXa generation dose-dependently.
Conclusion:
Supplementation with FX or pd-FVIIa/FX enhanced FVIIa/TF-induced activation of FX and increased coagulation potential in the AT-reduced plasma model of people with hemophilia.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Venous Thrombosis III: Interprofessional Care
Clot Retraction and Fibrinolysis
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

